IC-OS Working Group Webinar - Cardiac Amyloidosis: A Zebra or a Horse? - August 2021
Details
Jointly provided by The France Foundation and the International Cardio-Oncology Society
Target Audience
This educational activity is intended for the members of the cardiology and oncology healthcare teams who treat patients with cardiac amyloidosis, including physicians (cardiologists and hematologists/oncologists) and advance practice providers (nurse practitioners and PAs).
Statement of Need
There are significant challenges associated with the diagnosis and management of cardiac amyloidosis. While considered rare, this condition is almost certainly significantly underdiagnosed. Cardiac amyloidosis is influenced by several factors (eg, sex, age, geographic location, genetic factors, etc), is clinically heterogeneous, and can present as a number of other disorders (with subsequent delayed or misdiagnosis), and can take several years and visits to several different specialists before an accurate diagnosis is made.
Early diagnosis and intervention is critical (including distinguishing ATTR from AL and other amyloidoses), yet does not occur, typically as a consequence of the heterogeneity of the disease. Therapeutic options are indication-specific and are limited, but there are new and emerging agents with which clinicians may not be familiar. Given the limited awareness of CA, there is a significant need for education about CA and the importance of early multidisciplinary diagnosis and management, so that patients can have the best possible outcomes.
Educational Activity Learning Objective
Upon completion of this course, the participants should be able to:
Diagnose cardiac amyloidosis in a timely fashion
Activity Faculty
Kathleen W. Zhang, MD
Assistant Professor of Medicine, Cardio-Oncology Center of Excellence, Cardio-Oncology Center of Excellence, Washington University School of Medicine
Barry Trachtenberg, M.D. FACC
Assistant Professor of Medicine, Weill Cornell Medical College, Advanced Heart Failure Cardiology, Houston Methodist Hospital, Program Director, Advanced Heart Failure Fellowship, Director, Cardio-Oncology and Cardiac Amyloidosis Program, Heart Failure Chair, Texas Chapter ACC
Ariane Vieira Scarletelli Macedo, MD, MHS
Dra. Macedo is an assistant physician and coordinator of the cardio-oncology clinic at Santa Casa de São
Paulo School of Medicine, São Paulo, Brazil. She is also chair of the cardio-oncology department of Rede
D’Or São Luiz health network and researcher/faculty at BCRI (Brazilian Clinical Research Institute).
Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The France Foundation and the International Cardio-Oncology Society. The France Foundation is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation
Physicians:
The France Foundation designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Method of Participation/How to Receive Credit
- Review the activity objectives and CME/CE information.
- Participate in the CME/CE activity.
- Complete the CME/CE evaluation form, which provides each participant with the opportunity to comment on how participating in the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.
-
If you are requesting AMA PRA Category 1 Credit(s)™ or a certificate of participation—your CME/CE certificate will be available for download.
In accordance with the ACCME Standards for Commercial Support, The France Foundation and the International Cardio-Oncology Society require that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF and IC-OS resolve all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all their educational programs. Furthermore, TFF and IC-OS seek to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. [TFF and IC-OS are committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.
• Faculty and activity staff disclosures will be provided prior to the start of the activity.
Disclosure of Unlabeled Use
TFF and IC-SO require that CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental, and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF and IC-SO do not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.
Commercial Support Acknowledgment
This activity is supported by an educational grant from Janssen and Eidos Therapeutics Inc.
Organised by
Date
- America/New_York
Ariane Macedo
Dra. Macedo is an assistant physician and coordinator of the cardio-oncology clinic at Santa Casa...
Read MoreDra. Macedo is an assistant physician and coordinator of the cardio-oncology clinic at Santa Casa de São Paulo School of Medicine, São Paulo, Brazil. She is also chair of the cardio-oncology department of Rede D’Or São Luiz health network and researcher/faculty at BCRI (Brazilian Clinical Research Institute). Her clinical background includes MD and Master in Health Sciences at the University of Minas Gerais, Brazil. Currently, she is finishing the Ph.D. program at the Federal University of São Paulo, Brazil. She is an active member of scientific organizations serving now as Vice President of the cardio-oncology chapter of the Brazilian Society of Cardiology, Director of the Brazilian Society of Thrombosis and Hemostasis, and Member of the Council of Cardio-Oncology of the Interamerican Society of Cardiology. In 2019 she was certified to be a fellow of the European Society of Cardiology. She is currently developing consensus documents in cardio-oncology and the definition of core educational topics to provide structured training in cardio-oncology.
Show Less
Barry Trachtenberg
A cardiologist at Houston Methodist Hospital, Houston, Texas, US. Features in 1 video on Wondr...
Read MoreA cardiologist at Houston Methodist Hospital, Houston, Texas, US. Features in 1 video on Wondr Medical. Barry Trachtenberg generally speaks on Cardio-Oncology.
Show Less
Daniel Lenihan
Dr Lenihan has been active in cardio-oncology and heart failure, for over 20 years. The main...
Read MoreDr Lenihan has been active in cardio-oncology and heart failure, for over 20 years. The main focus of these efforts have included hemodynamic assessments, angiogenic growth factor response, novel cardiac biomarkers as well as optimal methods to prevent or detect heart failure at the earliest stage possible in patients undergoing treatment for cancer. His current research projects include early phase clinical trials in cardio-oncology, heart failure and amyloidosis. He is the Principal Investigator of the PROTECT study looking at cardiac safety in patients undergoing proteasome inhibitor treatment for relapsed multiple myeloma and the recently completed PREDICT study, a large multicenter prospective study examining the role of cardiac biomarkers for the detection of cardiotoxicity during anthracycline based therapy. In addition, he is intimately involved in the latest treatment trials for cardiac amyloidosis. He was recently at Washington University in St Louis to enhance and expand the Cardio-Oncology Center of Excellence. He is at the forefront of concerted efforts to develop a viable Cardio-Oncology fellowship training program and continues to foster collaboration among a host of colleagues both regionally, nationally, and throughout the world. He is the current President of the International Cardio-Oncology Society (ICOS),www.IC-OS.org, which is an international professional association whose primary goal is to eliminate cardiac disease as a barrier to effective cancer therapy.
Show Less
Kathleen Zhang
Dr. Zhang completed medical school and Internal Medicine residency at the University of...
Read MoreDr. Zhang completed medical school and Internal Medicine residency at the University of Pennsylvania, followed by fellowships in Cardiology and Cardio-Oncology at Washington University in St. Louis. She specializes in the cardiovascular care of patients with cancer as well as cardiac amyloidosis at Washington University in St. Louis. She has published over 20 peer-reviewed manuscripts in these areas, and served as an editor for the first edition of The Washington Manual of Cardio-Oncology. She is passionate about improving the diagnosis and treatment of patients with cardiac amyloidosis.
Show Less